(Oakbrook Terrace, IL – November 18, 2016 ) Bimeda, Inc. has acquired the marketing rights to Ceva Animal Health, LLC’s portfolio of equine products in the United States.
The U.S. portfolio comprises Tildren® (tiludronate disodium, NADA# 141-420), Altrenogest (ANADA# 200-481), ConfidenceEQ®, and PentosanEQ™. Bimeda also acquired the marketing rights for Tildren in Canada.
“This agreement is a key milestone in Bimeda’s strategic expansion into the Equine market. With a large portfolio of complementary products, Bimeda will now be in a strong position to serve the needs of equine customers in North America”, said Alan Kelly, Director of Commercial Development for Bimeda North America.
For more information please visit BimedaEquine.com.